A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza
between 18 - 65 years
an acute illness compatible with influenza infection (each of the following is required):
Oral temperature of ≥ 380C (obtained in office or self-measured within 12 hours prior to screening - if self-measured, subject must also have taken an antipyretic within 4 hours prior to screening) AND
At least one of the following respiratory symptoms (cough, sore throat, nasal obstruction) that is considered by the patient to be moderate or severe (greater than mild severity). AND
One of the following constitutional symptoms (fatigue, headache, myalgia, feverishness) that is considered by the patient to be moderate or severe (greater than mild severity).
Severe illness that will require hospitalisation.
Presence of any other pre-existing chronic infection that is undergoing or requiring medical therapy.
Flu Vaccination on or after 1/2/2013 - (getting clarified)